Loading…
Dr. Reddy's Laboratories Limited is projected to rise to $14.37 by 2027, a +11% move from its current price of $12.92. RDY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/14/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 15 | $12.66 | $12.92 | $13.19 | 0.00% |
| Jul 16 | $12.55 | $12.92 | $13.30 | +0.01% |
| Jul 17 | $12.47 | $12.92 | $13.39 | +0.01% |
| Jul 18 | $12.40 | $12.92 | $13.46 | +0.02% |
| Jul 19 | $12.35 | $12.92 | $13.53 | +0.02% |
| Jul 20 | $12.29 | $12.92 | $13.59 | +0.02% |
| Jul 21 | $12.24 | $12.92 | $13.64 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.24 | $12.92 | $13.64 | +0.03% |
| Week 2 | $11.98 | $12.93 | $13.95 | +0.05% |
| Week 3 | $11.77 | $12.93 | $14.20 | +0.08% |
| Week 4 | $11.61 | $12.93 | $14.41 | +0.11% |
| Week 5 | $11.46 | $12.94 | $14.60 | +0.14% |
| Week 6 | $11.34 | $12.94 | $14.77 | +0.16% |
| Week 7 | $11.22 | $12.94 | $14.93 | +0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dr. Reddy's Laboratories Limited is a healthcare company that operates as an integrated pharmaceutical company with a global footprint across North America, Europe, India, Russia, and international markets. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others.
The Global Generics segment markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations, and it also engages in the biologics business. The PSAI segment manufactures active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products, and provides contract research services. The Others segment develops therapies in oncology and inflammation and conducts research, development, and commercialization of differentiated formulations.
Its product offerings cover therapeutic categories including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, as well as vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
RDY trades at a current price of $13.99 and carries a market capitalization of $11.65B, with a rank of 852.
The price outlook is mixed in the near term but turns progressively more constructive over the forecast horizon. The 2026 forecast shows an average price of $13.99 within a range of $12.46 to $17.67, with neutral sentiment and 0% ROI.
Longer term, the forecasts project rising averages and meaningful ROIs: by 2027 the average is $15.93 with a 13.9% ROI and neutral sentiment; by 2028 the average is $17.01 with a 21.6% ROI and bullish sentiment; by 2030 the average is $21.96 with a 57% ROI and bullish sentiment; by 2040 the average is $48.49 with a 246.6% ROI and bullish sentiment; and by 2050 the average is $96.60 with a 590.5% ROI and bullish sentiment.
A major floor 12.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 19.0% above — a clean break opens room to run.
A major ceiling 25.4% above — clearing it would confirm fresh momentum.
Key RDY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RDY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.75 | Sell | $13.55 | Sell |
| MA 10 | $14.08 | Sell | $13.86 | Sell |
| MA 20 | $14.04 | Sell | $13.92 | Sell |
| MA 50 | $13.64 | Sell | $13.78 | Sell |
| MA 100 | $13.73 | Sell | $13.75 | Sell |
| MA 200 | $13.83 | Sell | $13.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.62 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -122.21 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.18 | Sell |
| ROC (12) | -11.87 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 34.17 | Neutral |
| Momentum (10) | -2.46 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 13.24 | Sell |
| ADX (14) | 16.59 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day technical picture is bullish on balance.
RSI(14) is 50, with a short-term momentum read around the midline. The chart shows the 50-day simple moving average at $13.58 and the 200-day simple moving average at $13.86, providing a near-term convergence around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.46 | $12.92 | $16.38 | 0% | Neutral | |
| $11.71 | $14.37 | $18.48 | +11% | Neutral | |
| $12.15 | $15.22 | $20.14 | +18% | Neutral | |
| $12.65 | $16.11 | $21.81 | +25% | Bullish | |
| $14.69 | $18.99 | $26.21 | +47% | Bullish | |
| $16.55 | $21.67 | $30.42 | +68% | Bullish | |
| $17.72 | $23.50 | $33.48 | +82% | Bullish | |
| $18.82 | $25.24 | $36.46 | +95% | Bullish | |
| $19.21 | $26.05 | $38.12 | +102% | Bullish | |
| $19.73 | $27.03 | $40.01 | +109% | Bullish | |
| $28.46 | $40.85 | $63.57 | +216% | Bullish | |
| $51.30 | $79.59 | $133.31 | +516% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.46 | $12.92 | $15.48 | +0.00% |
| August 2026 | $11.16 | $13.08 | $15.67 | +1.22% |
| September 2026 | $11.01 | $12.97 | $15.67 | -0.86% |
| October 2026 | $11.20 | $13.26 | $16.13 | +2.23% |
| November 2026 | $11.37 | $13.50 | $16.53 | +1.86% |
| December 2026 | $11.16 | $13.30 | $16.38 | -1.49% |
Click any year to see its month-by-month RDY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RDY to range from $12.46 to $16.38 through 2026. The $12.92 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The RDY price prediction for 2027 points to an average of $14.37 (low $11.71, high $18.48) — a potential gain of +11% on today's $12.92. A consolidation phase looks the most probable path here.
In 2028, RDY is projected to trade between $12.15 and $20.14, averaging $15.22 — a potential gain of +18% from today's $12.92. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
Dr. Reddy's Laboratories Limited's 2029 outlook centres on $16.11, within a $12.65 to $21.81 range. That is up +6% on the projected 2028 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, RDY could reach as high as $26.21, with a base case around $18.99 and support toward $14.69 — roughly +47% from $12.92. Momentum favours further upside here.
Expect RDY to range from $16.55 to $30.42 through 2031. The $21.67 average target implies a +68% move from current prices. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The RDY price prediction for 2032 points to an average of $23.50 (low $17.72, high $33.48) — a potential gain of +82% on today's $12.92. Momentum favours further upside here.
In 2033, RDY is projected to trade between $18.82 and $36.46, averaging $25.24 — a potential gain of +95% from today's $12.92. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Dr. Reddy's Laboratories Limited's 2034 outlook centres on $26.05, within a $19.21 to $38.12 range. That is up +3% on the projected 2033 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2035, RDY could reach as high as $40.01, with a base case around $27.03 and support toward $19.73 — roughly +109% from $12.92. Buyers look set to stay in control over this stretch.
Expect RDY to range from $28.46 to $63.57 through 2040. The $40.85 average target implies a +216% move from current prices. That is up +51% on the projected 2035 average. Momentum favours further upside here.
The RDY price prediction for 2050 points to an average of $79.59 (low $51.30, high $133.31) — a potential gain of +516% on today's $12.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in RDY today (≈ 77.399381 RDY) could be worth
$6,159.83
+$5,159.83 (+516%) by 2050 · US Dollar
Based on the average projected RDY price of $79.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RDYwould be worth at today's price.
$1,000 invested in RDY on Jul 14, 2025 (≈ 68.681317 RDY) would be worth
$887.36
-$112.64 (-11.3%) today · 0.89× · US Dollar
Based on a RDY entry price of $14.56 vs. today's $12.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.36 | $899.72 | -10.0% |
| 1 month ago | $13.3 | $971.43 | -2.9% |
| 3 months ago | $13.13 | $984.01 | -1.6% |
| 6 months ago | $13.3 | $971.43 | -2.9% |
| 1 year ago | $14.56 | $887.36 | -11.3% |
| All time (5.0y) ago | $14.51 | $890.54 | -10.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RDY forecast.
Our base-case forecast reaches $26.00 around 2034.
Implied market cap at $26.00: $21.65B
The multi-year forecast outlines a pronounced long-run upside despite a flat start in 2026. In 2026, the average price is $13.99 with a min of $12.46 and a max of $17.67, and the predicted ROI is 0% with neutral sentiment. By 2030, the average price rises to $21.96, with a max of $29.94 and a 57% ROI, signaling bullish momentum.
The forecast accelerates in the 2040s, with a 2040 average of $48.49, a max of $73.98, and a 246.6% ROI, maintaining a bullish sentiment. By 2050, the average is $96.60, the max $157.97, and the ROI stands at 590.5% with bullish sentiment. These figures illustrate substantial upside potential over the long term, while acknowledging that they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $21.96, a min of $17.15, a max of $29.94, and a projected ROI of 57%, with bullish sentiment.
The long-term forecast indicates rising averages and strong ROIs, with an average of $21.96 by 2030 and $96.60 by 2050 and ROIs of 57% and 590.5% respectively, though these are estimates and not guarantees.
Yes—the 2050 max forecast is $157.97, while the 2050 average is $96.60, indicating that reaching or exceeding $100 is within the forecast on the high end.
Current price is $13.99 and market cap is $11.65B.
The 2040 forecast shows an average price of $48.49, a min of $34.43, a max of $73.98, and a ROI of 246.6%, with bullish sentiment.
Dr. Reddy's Laboratories Limited Community Discussion
0Share your Dr. Reddy's Laboratories Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.